FIELD: chemistry.
SUBSTANCE: invention refers to biochemistry. There are described an antibody specifically binding to a human c-Met receptor and/or specifically inhibiting tyrosine kinase activity, containing a modified 'link' region of this receptor with an improved antagonist activity, containing the modified 'link' region, and a composition containing this anti-c-Met antagonist antibody and using it as a drug for cancer. There are described a nucleic acid coding this antibody, an expression vector containing the above nucleic acid, as well as a host cell containing the above vector.
EFFECT: invention extends the range of products for diagnosing diseases induced by hyperexpression or reduced expression of the c-Met receptor.
28 cl, 35 dwg, 4 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
| METHOD FOR MODELLING MONOCLONAL ANTIBODY ANTAGONISTIC ACTIVITY | 2009 |
|
RU2575600C2 |
| NEW ANTIBODIES INHIBITING C-MET DIMERISATION AND USING THEM | 2008 |
|
RU2552161C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| C-MET ANTAGONIST AND AMINOHETEROARYL COMBINATION FOR TREATING CANCER | 2009 |
|
RU2526171C2 |
| ANTI-MET ANTIBODIES AND THEIR USE | 2017 |
|
RU2765267C2 |
| HUMANISED MONOCLONAL ANTIBODIES TO HEPATOCYTE GROWTH FACTOR | 2007 |
|
RU2461570C2 |
| NOVEL ANTIBODY FOR DIAGNOSIS AND/OR PROGNOSIS OF CANCER | 2011 |
|
RU2651513C2 |
| CONJUGATES OF CMET ANTIBODY AND DRUG AND METHODS OF USING | 2017 |
|
RU2740996C2 |
| ANTI-cMet ANTIBODY AND USE THEREOF FOR DETECTION AND DIAGNOSIS OF CANCER | 2010 |
|
RU2582265C2 |
